Gothenburg, Sweden-based nanobiotechnology company Nanoxis has secured a SK1.75 million (€190,000) financing deal that will help it develop nanoanalytical platforms - so-called proteinchips - for the identification of proteins in drug discovery.
The company's CEO, Ahmet Senoglu, said Nanoxis is among the first Swedish companies building a product portfolio on inventions in the area of nanotechnology. "Nanoxis patent portfolio is based on outstanding research achievements and will open up new possibilities for fabrication of complex small scale devices in a number of application areas," including proteomics.
The company's technology platforms are based on liquid crystalline and polymeric materials, used in combination with proprietary nanofabrication protocols, that are used to make nanoscale devices. It relies on concepts such as self-assembly and self-organisation, as well as functionalities from embedded molecular entities.
In the short term, Nanoxis is focusing the development of platforms for separation and quantification of target proteins that are of importance to pharmaceutical and biotech companies. Further down the line, it intends to broaden its activities into the microelectronic and materials science market segments.
The investors are Creandum KB, the Technology Link Foundation in Gothenburg (TBSG), the Holding Company at the University of Göteborg (GU Holding AB) and AB Chalmersinvest.
The new funds complement soft financing - including start-up loans - as well as a research grant of SK 1.5 million from the Swedish Agency for Innovation Systems (VINNOVA)'s BioNanoIT programme.